Pharmaceutical Development Scientist & Expert Witness | CMC, Pre-formulation & Dosage Form Strategy | 40+ Years Guiding Global Pharma & Litigation

Overview

Seasoned pharmaceutical scientist and consultant with a career spanning large pharmaceutical organizations, innovative drug delivery companies, academia, and independent consulting. Expertise centers on preformulation, CMC, and dosage form development, with particular strength in salt selection, polymorphism, excipient compatibility, and dissolution method design. Regularly retained as an expert witness in high-stakes patent litigation and contract disputes, translating complex pharmaceutical data into clear opinions for courts and arbitration. Contributions extend to NIH grant review panels, journal editorial review, and extensive invited lectures and training on preformulation, controlled release, and development strategy. Engagement style emphasizes logical, data-driven methods, rigorous documentation, and practical problem solving that keeps programs on time, compliant, and scientifically robust.

Short Bio

Pharmaceutical development scientist and expert witness specializing in preformulation, CMC, and dosage form development across oral, parenteral, and advanced delivery systems. Background spans 20 years at a major pharmaceutical research institute, leadership of pilot plant operations at a novel 3D-printing drug delivery company, and nearly three decades of independent consulting and expert witness work. Widely published and frequently invited to speak, review grants, and referee manuscripts in pharmaceutical science.

What I Bring

Over 40 years of hands-on experience in pharmaceutical development across discovery, preclinical, clinical, and commercial stages
Deep expertise in preformulation/physical pharmacy, including salt selection, polymorph management, solubility enhancement, and excipient compatibility
Proven track record authoring and reviewing CMC sections of INDs and NDAs, pharmaceutical development reports, and process validation documentation
Extensive expert witness experience in Paragraph IV Hatch-Waxman and Canadian Notice of Allegation patent litigation, including claim construction and technical analysis
Strong ability to translate complex scientific data into clear, defensible expert reports and courtroom testimony
Leadership in pilot plant operations, including GLP and cGMP batch manufacture, SOP design, and quality/compliance oversight
Broad experience managing outsourced development programs and CDMO relationships with multi-million-dollar budgets
Recognized thought leadership through peer-reviewed publications, conference symposia, and technical magazine articles
Longstanding engagement with NIH, professional societies, and journal editorial boards as a reviewer, advisor, and officer
Demonstrated capability to rescue problematic development programs through structured problem-solving and QbD-style approaches

Key Technologies & Product Expertise

Preformulation and physical pharmacy methods (pKa, log P, solubility profiles, vapor pressure determination)
Solid-state characterization including XRPD, particle size analysis (electrozones, image analysis, diffraction light scattering), and polymorph monitoring
Excipient compatibility testing (DSC methods, isothermal stress wet-granulation simulation)
Oral solid dosage forms: IR, ER, CR, SR tablets and capsules, softgels, gelcaps, orally disintegrating tablets (ODT)
Parenteral dosage forms including injections, oil-based formulations, IV emulsions, and sterile drug products
Controlled/extended release dosage forms via salt selection and solubility modification
Novel drug delivery systems including 3D-printed dosage forms and tissue engineering (bone replacement devices)
Iontophoretic delivery systems and transdermal delivery optimization via log P-SAR models
Dissolution method development and validation for IR, ER, SR, CR, and topical/transdermal systems
GLP and cGMP manufacturing of clinical and registration batches, including pilot plant operations and process validation
IND and NDA CMC documentation, including methods development history, analytical method validation, dissolution rationale, and dosage form development history
Specification setting and regulatory response for particle size, polymorphic form, dissolution rate, and related attributes
Quality by Design (QbD) approaches to salt form and dosage form selection
Regulatory and legal interfaces: Hatch-Waxman Paragraph IV, Canadian NOA, claim construction, and patent prosecution history analysis
SOP development and harmonization across client/vendor and intramural procedures

Titles Held

Principal / President, Consultant and Expert Witness Services – 2018–Present
Principal / President, pharmaceutical consulting and expert witness corporation (independent) – 2002–2017
Vice President, FAC Consulting, Inc., Pharmaceutical Consultant – 1996–1997
Assistant Director for Pilot Plant Laboratory Operations, Therics, Inc. – 1999–2001
Manager, Pilot Plant Operations, Therics, Inc. – 1997–1999
Research Manager, Physical Pharmacy, The R.W. Johnson Pharmaceutical Research Institute (Johnson & Johnson Family of Companies) – 1991–1996
Group Leader, Physical Pharmacy, The R.W. Johnson Pharmaceutical Research Institute – 1989–1990
Group Leader, Physical Pharmacy, McNeil Pharmaceutical Corporation / McNeil Laboratories – 1986–1988
Principal Scientist, Basic Pharmaceutics Section, McNeil Pharmaceutical Corporation / McNeil Laboratories – 1980–1986
Senior Scientist / Research Scientist, Basic Pharmaceutics Section, McNeil Pharmaceutical Corporation / McNeil Laboratories – 1976–1979
Adjunct Assistant Professor, College of Pharmacy, University of Cincinnati – 1983–1993
Assistant Professor, Pharmacy Department, Northeastern University College of Pharmacy and Allied Health Professions – 1975–1976
Assistant Professor, Department of Pharmaceutics, Massachusetts College of Pharmacy – 1974–1975

Career Highlights

Provided expert witness services in numerous high-profile U.S. Paragraph IV Hatch-Waxman and Canadian Notice of Allegation cases involving leading branded products (e.g., proton pump inhibitors, cardiovascular agents, antiretrovirals, combination products), supporting both innovator and generic companies as appropriate.
Authored multiple expert reports on issues including formulation differences, polymorphism, particle size, excipient function, patent validity/invalidity, claim construction, and patent prosecution history, as well as testifying at deposition and trial, including cases where clients prevailed.
Served as consultant to multinational, large, mid-size, and virtual pharmaceutical companies on CMC and preformulation problems, in-licensing reviews, and due diligence, spanning products such as ULTRAM (tramadol ER), REVLIMID (lenalidomide polymorphs), fenfluramine, and multiple OTC softgel and sterile injectable products.
Managed outsourced development of three Phase III and registration-stage programs for Ferring USA, including ENDOMETRIN progesterone effervescent vaginal tablets, HCG sterile injections, and a decapeptide iontophoretic delivery system, each with budgets exceeding $6 million, while authoring issue-free CMC submissions.
Established and led a dual-function pilot plant at Therics, Inc. capable of both non-cGMP development and fully cGMP-compliant clinical and demonstration batches for 3D-printed drug delivery and bone replacement devices, including SOPs, inventory systems, and regulatory-compliant documentation.
Pioneered departmental adoption of advanced particle sizing and XRPD methodologies at Johnson & Johnson companies to monitor polymorphism and optimize salt forms from discovery through commercialization, significantly enhancing control of solid-state properties across multiple NCE programs.
Developed, validated, and published model preformulation methods for salt and polymorph selection, corrosion testing, excipient compatibility, and dissolution methods, which were adopted for internal development and contributed to broader industry practice.
Authored 19 peer-reviewed manuscripts, 12 meeting abstracts, 26 invited symposia topics, seminars and courses, and several technical magazine articles, covering topics such as preformulation strategy, controlled release candidate selection, vapor pressure determination, and SOP best practices.
Held numerous leadership roles within AAPS, including Pharmaceutical Technologies Section Chair and Past-Chair, and served as symposium moderator for the Contract Pharma Contracting and Outsourcing Conference over many years.
Participated in NIH NIAID Special Emphasis Panels and advisory committees focused on therapeutic countermeasures for biodefense, AIDS, and emerging infectious diseases, contributing to the evaluation of grant applications and translational research programs.

Education & Professional Certifications

Ph.D., Pharmaceutics, Philadelphia College of Pharmacy and Science, 1975
M.S., Pharmaceutics, Philadelphia College of Pharmacy and Science, 1972
B.S., Pharmacy, Philadelphia College of Pharmacy and Science, 1968
National Science Foundation (NSF) Trainee, Philadelphia College of Pharmacy and Science, 1970–1971
American Foundation for Pharmaceutical Education (AFPE) Fellow, Philadelphia College of Pharmacy and Science, 1971–1974
Registered Pharmacist (R.Ph.), New Jersey, 1970–2017 (retired)
Registered Pharmacist (R.Ph.), Florida, 2010–2015 (retired)
Immunizing Pharmacist, New Jersey, 2010–2013 (retired)

Languages

English- Native

Impact

Advanced industry practice in preformulation by developing and disseminating practical methods for salt and polymorph selection, excipient compatibility, and controlled release candidate evaluation.
Strengthened regulatory submissions for multiple NCEs and line extensions through well-constructed CMC sections, technical reports, and specification strategies that withstood regulatory scrutiny.
Enabled clients to successfully navigate complex patent and contract disputes through rigorous expert analysis, clear written opinions, and credible courtroom testimony.
Improved development efficiency and compliance through pilot plant design, SOP standardization, and robust documentation frameworks for GLP/cGMP manufacturing.
Influenced the broader scientific community via peer-reviewed publications, invited symposia, and long-term service as a reviewer and leader within professional societies and NIH panels.